Intraocular pressure effects of pegaptanib (macugen) injections in patients with and without glaucoma.
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D052157:Aptamers, Nucleotide / Q000627:therapeutic use*; D002908:Chronic Disease; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects*; D008268:Macular Degeneration / Q000188:drug therapy; D014065:Tonometry, Ocular; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D052157:Aptamers, Nucleotide; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib